Research Associate
0755-88015583
南方科技大学医学院B栋502
tianxx@sustech.edu.cn

Work Experience:
2017.4-2018.11,Tianjin International Joint Academy of Biomedicine-Tianjin Kemei Biotechnology Co., Ltd. Laboratory Technicia.
2018.12-2019.7Research Associate, School of Medicine, Southern University of Science and Technology.
2019.8-present, Research Associate,School of Medicine, Southern University of Science and Technology.

Education:
2007.9-2011.6,B.Sc. in College of Life Sciences  Nankai University, College of Life Sciences
2009.9-2010.6,Chinese University of Hong Kong, Visiting Students
2011.8-2016.12,Ph.D. in Biochemistry. Texas A&M University
Selected publications
1. Fangfang Tao#, Xinxin Tian#, ShanmingRuan, Minhe Shen and Zhiqian Zhang*, miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma. FASEB Journal, 2018; fj201800495RR. (共同一作)

2. Fangfang Tao#, Xinxin Tian#, Mengxi Lu# and Zhiqian Zhang*, A novel lncRNA, Lnc-OC1, promotes ovarian cancer cell proliferation and migration by sponging miR-34a and miR-34c. Journal of Genetics and Genomics, 2018; 45: 137-145. (共同一作)

3. Xinxin Tian and Zhiqian Zhang*, miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer. IUBMB life, 2018; 70: 71-80. 

4. Xinxin Tian#, Fangfang Tao#, Baotong Zhang, Jin-Tang Dong,Zhiqian Zhang*, The miR-203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK-3β/β‐CATENIN signal pathway, IUBMB Life, 2018; 70: 224-236. 

5. ShanmingRuan#, Zhiqian Zhang#, Xinxin Tian#, Dawei Huang#, Wenhong Liu, Bo Yang, Minhe Shen, and Fangfang Tao*, Compound Fuling Granule Suppresses Ovarian Cancer Development and Progression by disrupting mitochondrial function, galactose and fatty acid metabolism. J Cancer. 2018; 9(18):3382-3393. (共同一作)

6. Fangfang Tao#, Xinxin Tian# and Zhiqian Zhang#: The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression. Oncotarget 9: 12212-12225, 2018.(共同一作)